Clinical trials: Diffuse Scleroderma
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc
Influenza Vaccine in Scleroderma
Influenza Vaccination in Patients With Scleroderma
The safety and efficacy of vaccination against influenza in patients with scleroderma is not clear. The objective of this study is to assess its safety and efficacy in 50 patients with scleroderma in comparison with 30 controls
- Trial name
- NCT01002508
- Testing
- Influenza vaccine
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Scleroderma
Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples
The aim is to find the presence of anti vitamin D antibodies in scleroderma patients and compare with control. A second goal is anti vitamin D levels in serum of scleroderma patients in relation to the clinical manifestations of…
- Trial name
- SSc (NCT01553890)
- Testing
- Blood sample
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Systemic Sclerosis
Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc)
The goal of this clinical trial is to gather information on the RENEW app used by people with scleroderma. Specifically, the researchers want to learn more about RENEW by collecting information about the rates of recruitment…
- Trial name
- RENEW (NCT07402863)
- Testing
- RENEW
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan
Systemic Sclerosis (SSc)
Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)
The objective of the study is to establish an in vitro model using iPSCs to test the hypotheses developed. The primary objective is to generate, via the SAFE-IPS platform, 8 iPSC lines derived from blood samples taken from: Two…
- Trial name
- hiPSSS (NCT07650565)
- Testing
- Blood Sample Collection
- Where
- France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Primary Gougerot-Sjögren Syndrome, Systemic Sclerosis, Diffuse
Quantification and Characterization of Circulating Epithelial and Endothelial Cells in Gougerot-Sjögren Syndrome, Compared to Systemic Sclerosis
Primary Gougerot-Sjögren's syndrome is a systemic autoimmune disease belonging to the group of connectivities, whose physiopathology remains largely unknown.
- Trial name
- CIRCEE (NCT05528809)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Montpellier
Graft Versus Host Disease, Systemic Scleroderma
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
This randomized phase II trial is evaluating how well imatinib mesylate works compared to rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host disease (GVHD).
- Trial name
- NCT01309997
- Testing
- imatinib mesylate, rituximab
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Lee, Stephanie
Systemic Lupus Erythematosus, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
To evaluate the safety and efficacy of CD19-CAR-DNT cells in subjects with relapsed/refractory autoimmune diseases
- Conditions
- Systemic Lupus Erythematosus, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis
- Trial name
- NCT06316076
- Testing
- CD19-CAR-DNT cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- RenJi Hospital
Scleroderma, Systemic
A Comparison Between Two Educational Methods in the Rehabilitation of the Microstomia in Systemic Sclerosis
Background: A typical feature of SSc is the fibrotic involvement of the connectival tissue of the face, which causes microstomia.
- Trial name
- SScM398-1 (NCT03766243)
- Testing
- Brochure and DVD plus nursing training, Brochure and DVD only
- Volunteers
- 39 people
- Sponsor
- IRCSS Istituto Dermopatico dell'Immacolata, Fondazione Luigi Maria Monti
Systemic Sclerosis, Preeclampsia
Is a History of Pre-eclampsia a Risk Factor for Vascular Phenotype in Women With Systemic Sclerosis?
Background: Pre-eclampsia, defined by the association of an arterial hypertension and significant proteinuria after 20 weeks of gestation, complicates 1 to 2% of pregnancies in France.
- Conditions
- Systemic Sclerosis, Preeclampsia, Vascular Complications
- Trial name
- PREVASCLERO (NCT04363021)
- Where
- 10 sites in France
- Volunteers
- 378 people
- Sponsor
- University Hospital, Brest
Primary Raynaud Disease, Systemic Sclerosis
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
Ve-cadherin is expressed in endothelial cells. Systemic slerosis is a rare auto-immune disease with a endothelial dysfunction. This study is to evaluated the level of soluble VE-cadherin and VE-cadherin antibody in patients with…
- Trial name
- Sclerocadh1 (NCT02212249)
- Testing
- soluble Ve cadherin
- Where
- France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Grenoble
Scleroderma, Systemic
Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Progressive systemic sclerosis (SSc) is an immune-based disease that causes abnormal connective tissue growth of the skin and internal organs. At this point, there are no effective therapies for treating SSc.
- Trial name
- NCT00418132
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Scleroderma, Digital Ulcers
Riociguat in Scleroderma Associated Digital Ulcers
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with…
- Trial name
- RESCUE (NCT02915835)
- Testing
- Riociguat
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dinesh Khanna, MD, MS
Systemic Sclerosis
Sleep Quality, Stress, Depression, Blood Pressure Responses to Diaphragmatic Respiratory Exercise in Systemic Sclerosis
systemic sclerosis women usually report problems such as stress/depression, fatigue, not deep sleep. complementary therapies may improve the reported problems in those patients
- Trial name
- NCT05623917
- Testing
- Tele-supervised diaphragmatic respiratory exercise
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Systemic Sclerosis, Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension in Systemic Sclerosis
The purpose of this study is to evaluate the role of stress echocardiography, compared to standard echocardiography in the early identification of pulmonary arterial hypertension in systemic sclerosis.
- Trial name
- NCT00617487
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Systemic Sclerosis, Scleroderma
Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
This study investigates the efficacy and safety of STI571 for the treatment of fibrosis in participants with systemic sclerosis.
- Trial name
- NCT00613171
- Testing
- STI571
- Where
- 7 sites in United States, Germany and 3 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Tibial Delayed Healing
Tibial Delayed Healing Pivotal Clinical Trial
Evaluate the INFUSE/MASTERGRAFT™ Delayed Healing Device as an alternative/replacement to autograft in the treatment of tibial delayed healing.
- Trial name
- NCT01016067
- Testing
- INFUSE/MASTERGRAFT, Autograft bone
- Where
- 16 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Medtronic Spinal and Biologics
Scleroderma (Limited and Diffuse), Undifferentiated Connective Tissue Disease
Metabolomic Analysis of Systemic Sclerosis
Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years.
- Conditions
- Scleroderma (Limited and Diffuse), Undifferentiated Connective Tissue Disease, Raynaud Disease, Vascular Disease
- Trial name
- SCLEROMICS (NCT02298777)
- Testing
- - Skin biopsy - Urine sample - Blood sample
- Where
- 4 sites in France
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Systemic Sclerosis
Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy
The aim of this prospective study is to determine prevalence and characteristics of small intestinal mucosal abnormalities in 40 patients with systemic sclerosis, using capsule endoscopy.
- Trial name
- sclero-video (NCT00958672)
- Testing
- Endoscopic capsule
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Rouen
Scleroderma, Systemic, Scleroderma, Diffuse
Phenotyping of Chronic Pain in Diffused Systemic Scleroderma
The primary objective of the study is to describe the different phenotyping of pain in systemic scleroderma patients and perturbations of mechanisms of the pain.
- Trial name
- PAIN SSc (NCT05622578)
- Testing
- QST, CPM and Paisudoscan
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris